Loading...
XSTO
VICO
Market cap219mUSD
Jun 12, Last price  
8.84SEK
1D
-4.23%
1Q
20.11%
Jan 2017
-45.16%
IPO
67.58%
Name

Vicore Pharma Holding AB

Chart & Performance

D1W1MN
P/E
—
P/S
18.96
EPS
—
Div Yield, %
—
Shrs. gr., 5y
21.02%
Rev. gr., 5y
-11.73%
Revenues
109m
3,3143,305,0001,571,000840,000852,000932,000508,00000000109,346,000
Net income
-169m
L-45.77%
-3,158-1,603,00013,687,000-4,570,000-6,652,000-12,855,000-21,681,000-93,084,000-146,862,000-296,481,000-288,422,000-310,942,000-168,634,000
CFO
-165m
L-33.91%
-1,669-1,793,000-2,825,000-3,682,000-7,251,000-7,705,000-33,036,000-86,999,000-119,935,000-265,171,000-299,919,000-249,583,000-164,946,000
Earnings
Aug 20, 2025

Profile

Vicore Pharma Holding AB (publ) engages in the research and development of pharmaceutical products for the treatments for rare lung diseases. The company is developing VP01, a small molecule compound for oral administration that is in phase II clinical trial for the treatment of interstitial lung diseases, idiopathic pulmonary fibrosis (IPF), systemic sclerosis, and COVID-19; and VP02, a formulation and delivery route for an existing immunomodulatory compound, which is preclinical trials to treat patients with IPF. It has a cooperation and development agreement with Emeriti Bio AB; license agreement with Nanologica AB (publ); and a collaboration agreement with Alex Therapeutics AB for the development and clinical validation of a digital therapeutic (DTx) built on the Alex DTx platform. The company was formerly known as Mintage Scientific AB. Vicore Pharma Holding AB (publ) was founded in 2000 and is headquartered in Gothenburg, Sweden.
URL
https://vicorepharma.com/
IPO date
Dec 10, 2015
Employees
23
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
109,346
 
Cost of revenue
299,706
320,889
291,106
Unusual Expense (Income)
NOPBT
(190,360)
(320,889)
(291,106)
NOPBT Margin
Operating Taxes
(256)
(384)
(384)
Tax Rate
NOPAT
(190,104)
(320,505)
(290,722)
Net income
(168,634)
-45.77%
(310,942)
7.81%
(288,422)
-2.72%
Dividends
Dividend yield
Proceeds from repurchase of equity
882,143
500,406
187,292
BB yield
-93.43%
-36.55%
-14.49%
Debt
Debt current
65
Long-term debt
65
Deferred revenue
Other long-term liabilities
556
898
1,600
Net debt
(1,156,001)
(482,766)
(261,678)
Cash flow
Cash from operating activities
(164,946)
(249,583)
(299,919)
CAPEX
(3,000)
Cash from investing activities
149,038
(144,455)
74,000
Cash from financing activities
834,063
470,855
187,040
FCF
(190,079)
(320,476)
(290,692)
Balance
Cash
1,156,001
482,766
261,743
Long term investments
Excess cash
1,150,534
482,766
261,743
Stockholders' equity
(1,218,401)
(921,728)
Invested Capital
1,129,885
1,674,688
1,211,716
ROIC
ROCE
EV
Common stock shares outstanding
111,734
96,559
72,214
Price
8.45
-40.41%
14.18
-20.78%
17.90
28.59%
Market cap
944,152
-31.04%
1,369,204
5.92%
1,292,638
33.27%
EV
(211,849)
886,438
1,030,961
EBITDA
(190,360)
(317,596)
(287,494)
EV/EBITDA
1.11
Interest
8
358
8
Interest/NOPBT